General Allocation of Responsibilities. The Parties anticipate that (i) Alexion will be primarily responsible for pre-clinical animal modeling and associated experiments, and in vitro luciferase and CD34 assays, as well as clinical laboratory and regulatory support, and (ii) XOMA will be primarily responsible for toxicology and certain other pre-clinical work pursuant to the Development Plan, fermentation development, master cell bank preparation, purification development, quality assurance, quality control, pre-IND Manufacturing, and GMP Manufacture of clinical supplies of Products. Subject to the approval of the JMC, each Party shall be permitted to engage academic, research, or other non-commercial institutions or contract service organizations to conduct Development activities on Products.
General Allocation of Responsibilities. 4.1. The Parties must clearly define their obligations and corresponding obligations to comply with the GDPR requirements.
General Allocation of Responsibilities. Generally, except as otherwise expressly provided herein, with respect to each Program, Targacept shall be solely responsible for conducting all research, discovery and Development activities, and for all costs and expenses associated therewith, with respect to the corresponding Research Program during its Research Program Term (except for the Pain 1 Program, for which there is no Research Program) and the corresponding Early Development Programs during their respective Early Development Program Terms and shall have the right, but not the obligation, to conduct Targacept Post-Exercise Activities after exercise by GSK of its Program Option with respect to such Program. Targacept shall carry out all such activities with respect to each of the Programs pursuant to the applicable Research Plan and Early Development Plan. Subject to Targacept’s rights with respect to the Targacept Post-Exercise Activities, GSK shall be solely responsible for all development and commercialization activities, and for all costs and expenses associated therewith, with respect to Product Candidates and Licensed Products.
General Allocation of Responsibilities. The Development Plans shall allocate Development tasks between the Parties consistent with optimizing the Development of Products. The Parties anticipate that (i) Aphton will be primarily responsible for investigating, recommending and delivering the Target Antigen(s), (ii) XOMA will be primarily responsible for (A) generating Human Engineered(TM) or other antibodies or fragments thereof to the Target Antigen(s) and (B) developing processes for manufacture of antibodies or fragments thereof, including formulation and analytical methods and (iii) the Parties will share the responsibility for characterizing and testing antibodies or fragments thereof generated by XOMA for activity against the Target Antigen(s) in appropriate in vitro and in vivo models.
General Allocation of Responsibilities. Subject entirely to the more detailed provisions set forth elsewhere in this Agreement, (a) each Party will conduct Target identification work in its sole discretion, (b) both Parties will conduct research and development work relating to Collaboration Targets and Collaboration Products in accordance with R&D Plans and Budgets, (c) XOMA will be responsible for manufacture of pre-clinical supplies and supplies for Phase I and Phase II Clinical Trials of Collaboration Products, and (d) Chiron will be responsible for Commercialization of Collaboration Products.
General Allocation of Responsibilities
